Robert Greenberg Skechers Usa Inc (SKX) insider trading activity

Robert Greenberg is Chief Executive Officer of SKECHERS USA INC. Currently has a direct ownership of 51,342 shares of SKX, which is worth approximately $2.9 Million. The most recent transaction as insider was on Mar 03, 2025, when has been sold 40,924 shares (Class A Common Stock) at a price of $60.76 per share, resulting in proceeds of $2,486,542. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 51.3K

61.33% 3M change

61.33% 12M change

Total Value Held $2.9 Million

ROBERT GREENBERG Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	SELL Open market or private sale	$2,486,542 $60.76 p/Share	40,924 Reduced 44.35%	51,342 Class A Common Stock
Mar 01 2025	SELL Payment of exercise price or tax liability	$2,575,363 $60.99 p/Share	42,226 Reduced 31.4%	92,266 Class A Common Stock
Feb 14 2025	BUY Grant, award, or other acquisition	-	73,125 Added 35.22%	134,492 Class A Common Stock
Feb 12 2025	SELL Open market or private sale	$3,299,072 $62.72 p/Share	52,600 Reduced 46.15%	61,367 Class A Common Stock
Feb 11 2025	SELL Payment of exercise price or tax liability	$3,416,477 $63.9 p/Share	53,466 Reduced 31.93%	113,967 Class A Common Stock
Jan 02 2025	SELL Bona fide gift	-	12,330 Reduced 6.86%	167,433 Class A Common Stock
Dec 30 2024	SELL Payment of exercise price or tax liability	$858,012 $67.72 p/Share	12,670 Reduced 0.71%	1,779,763 Class A Common Stock
Mar 15 2024	SELL Open market or private sale	$1,854,016 $61.11 p/Share	30,339 Reduced 18.6%	132,783 Class A Common Stock
Mar 15 2024	BUY Grant, award, or other acquisition	-	59,650 Added 23.49%	194,333 Class A Common Stock
Mar 14 2024	SELL Payment of exercise price or tax liability	$1,914,829 $61.42 p/Share	31,176 Reduced 16.05%	163,122 Class A Common Stock
Mar 14 2024	BUY Grant, award, or other acquisition	-	61,515 Added 24.05%	194,298 Class A Common Stock
Mar 04 2024	SELL Open market or private sale	$1,905,818 $61.08 p/Share	31,202 Reduced 19.03%	132,783 Class A Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$1,998,611 $62.33 p/Share	32,065 Reduced 16.36%	163,985 Class A Common Stock
Feb 08 2024	SELL Payment of exercise price or tax liability	$5,705,755 $57.97 p/Share	98,426 Reduced 25.01%	295,189 Class A Common Stock
Feb 08 2024	SELL Open market or private sale	$5,737,173 $57.87 p/Share	99,139 Reduced 33.58%	196,050 Class A Common Stock
Feb 07 2024	BUY Grant, award, or other acquisition	-	197,565 Added 33.42%	393,615 Class A Common Stock
Jan 02 2024	SELL Open market or private sale	$784,157 $62.21 p/Share	12,605 Reduced 6.04%	196,050 Class A Common Stock
Dec 30 2023	SELL Payment of exercise price or tax liability	$772,704 $62.34 p/Share	12,395 Reduced 5.61%	208,655 Class A Common Stock
Mar 10 2023	BUY Grant, award, or other acquisition	-	77,300 Added 23.89%	246,207 Class A Common Stock
Mar 06 2023	SELL Bona fide gift	-	9,453 Reduced 4.1%	221,050 Class A Common Stock
Mar 02 2023	SELL Open market or private sale	$426,897 $45.16 p/Share	9,453 Reduced 5.3%	168,907 Class A Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$842,680 $45.32 p/Share	18,594 Reduced 9.44%	178,360 Class A Common Stock
Feb 01 2023	SELL Bona fide gift	-	12,604 Reduced 5.18%	230,503 Class A Common Stock
Jan 03 2023	SELL Payment of exercise price or tax liability	$520,012 $41.95 p/Share	12,396 Reduced 6.01%	193,854 Class A Common Stock
Mar 02 2022	SELL Open market or private sale	$3,684,094 $43.3 p/Share	85,083 Reduced 29.2%	206,250 Class A Common Stock

Also insider at

LIXT

LIXTE BIOTECHNOLOGY HOLDINGS, INC. Healthcare

> 10% Shareholder